Metabolomic Profiling of Novel Mediators of Vascular Function

Brigham and Women's Hospital1 site in 1 country48 target enrollmentMay 2007

ConditionsType 2 Diabetes Mellitus

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type 2 Diabetes Mellitus
Sponsor: Brigham and Women's Hospital
Enrollment: 48
Locations: 1
Primary Endpoint: change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements
Status: Terminated
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to identify and characterize specific chemicals and metabolic pathways that change with forearm ischemia. These changes will be compared with forearm blood flow and flow-mediated vasodilation of the brachial artery.

Registry

clinicaltrials.gov

Start Date

May 2007

End Date

February 2018

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Brigham and Women's Hospital

Responsible Party

Principal Investigator

Joshua A. Beckman, MD

Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

•Adults age 18 or older
•Type 2 diabetes mellitus

Exclusion Criteria

•Type 1 diabetes mellitus
•Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin \[pramlintide\]), or incretin mimetics (Byetta \[exenatide\])
•Pregnancy
•Uncontrolled hypertension, \> 180/100 mmHg